SLC9A3R1

If you have had a kidney stone in your twenties or thirties, a parent or sibling with recurrent stones, or an unexplained fracture in a long bone, your genes may be part of the story. SLC9A3R1 is one of a handful of genes that, when carrying certain rare variants, can quietly shift how your kidneys hold onto phosphate and how your bones build themselves.

This test reads your two copies of the SLC9A3R1 gene to look for variants that may raise your risk for stone disease and bone fragility. The result is fixed for life, but knowing it changes what you monitor, what specialists you involve, and how aggressively you treat the conditions it can produce.

What This Gene Actually Does

SLC9A3R1 (sometimes called NHERF1 or EBP50) makes a scaffolding protein, a kind of molecular docking station that holds other proteins in the right place inside cells. In the kidneys, it helps anchor the transporters that decide how much phosphate gets reabsorbed back into the blood versus lost in urine. In immune cells, it helps organize the surface contact between two T cells (called the immune synapse), the meeting point where your immune system coordinates its response.

In a large study of people with two non-working copies of various genes, individuals lacking working SLC9A3R1 showed measurable shifts in chemical messengers that control calcium and phosphate, confirming that this gene helps run your mineral metabolism. When the scaffold is broken, the transporters it normally holds in place do not work as well, and minerals can leak out where they should be held back or build up where they should not.

Kidney Stone Risk

The strongest clinical signal for SLC9A3R1 comes from kidney stone disease. In a study of 51 people with early-onset stone or kidney calcium buildup (nephrocalcinosis), whole-gene sequencing identified dominant SLC9A3R1 mutations as the single inherited cause in some families. These are not common variants. They are rare, but when present, they can drive disease on their own.

Two larger adult studies put this in perspective. In a cohort of 787 adult stone formers, rare likely-harmful variants in SLC9A3R1 and related genes were significantly enriched compared with the general population, even though full-blown inherited stone disease remained uncommon. A follow-up study of 901 adults with stone disease found that carrying a rare variant in one of these genes carried real prognostic weight, with carriers showing higher stone recurrence over three years of follow-up.

What this means for you: if you carry a variant, the biochemical clues may be subtle on a routine panel, but your kidneys are working with a weaker version of this scaffolding system. That deserves closer monitoring of urine calcium, urine phosphate, and stone formation, even if your last stone seemed like a one-off.

Bone Health and Atypical Femur Fractures

Atypical femur fractures are unusual breaks in the thigh bone that happen with little or no trauma, sometimes after long-term use of bone-protection drugs like bisphosphonates. In a study of 25 patients with these fractures, rare variants in SLC9A3R1 (and a related phosphate-handling gene, SLC34A1) appeared at much higher frequency than expected, leading the researchers to propose SLC9A3R1 as a possible inherited risk factor for these fractures. The link runs through a condition called NPHLOP2, a disorder of phosphate and bone mineral handling.

What this means for you: if you have a personal or family history of an atypical femur fracture, or if you are considering long-term bone medication, knowing your SLC9A3R1 status adds context to a decision your bone doctor cannot otherwise make from blood work alone.

Psoriasis Risk

A common variant sitting in the DNA between SLC9A3R1 and a neighboring gene called NAT9 is linked to psoriasis, an autoimmune skin condition. This variant eliminates a binding spot for a regulator protein called RUNX1, which normally tells nearby genes when to turn on. SLC9A3R1 is most active in the upper layers of skin (both healthy and psoriatic) and in resting T cells, so disrupting this regulator likely changes how skin cells and immune cells coordinate.

This is a susceptibility variant, not a deterministic one. Carrying it does not mean you will get psoriasis, but it may stack with other genetic and environmental factors. If you have psoriasis or a strong family history, the genetic context is one more data point, not a verdict.

What a Single Reading Tells You

Unlike a blood test that fluctuates with your meals, sleep, and stress, your SLC9A3R1 genotype is fixed at conception. One test gives you the answer for life. You do not retest a genetic result the way you retest cholesterol.

What does need ongoing tracking are the biological systems this gene influences: calcium and phosphate in blood, calcium and oxalate in urine, parathyroid hormone, vitamin D, kidney function, and bone density. If you carry a variant, those numbers become more meaningful and worth checking at least annually. A baseline genetic test plus regular downstream monitoring is more useful than any single snapshot.

When Results Need Careful Interpretation

SLC9A3R1 testing is still emerging in clinical practice, and a few things can muddy interpretation:

• Variant of uncertain significance: many rare changes in the gene have unknown clinical meaning, and labs vary in how they classify them. A reported variant is not always actionable.
• Incomplete penetrance: carrying a likely harmful variant does not guarantee disease. In adult kidney stone cohorts, biochemistry was often subtle in carriers, and many carriers had milder disease than the genetics alone would predict.
• Genetic context matters: SLC9A3R1 variants often interact with other phosphate-handling genes (like SLC34A1). A single-gene result without broader genetic context can be misleading.

What To Do If You Carry a Variant

A positive or uncertain result is the start of a workup, not the end. Reasonable next steps include checking serum calcium, phosphate, vitamin D, and parathyroid hormone to see how your mineral handling looks in real life. A 24-hour urine collection can show whether your kidneys are losing calcium or phosphate inappropriately. A bone density scan gives a structural baseline. Kidney function tests, including creatinine and cystatin C, round out the picture.

If your downstream biochemistry shows real disturbances, a nephrologist (kidney specialist) or endocrinologist (hormone and bone specialist) can help decide whether to treat. If your biochemistry looks clean despite the variant, watchful monitoring is reasonable, with rechecks at least once a year and sooner if symptoms appear. First-degree relatives may also want to consider testing, since the variants are inherited and stone disease and fragile bones tend to run in families.